IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection

Ann Hematol. 2020 Dec;99(12):2953-2956. doi: 10.1007/s00277-020-04160-w. Epub 2020 Jun 25.
No abstract available

Keywords: Hematological malignancies; IL-1R blockade; SARS-CoV-2.

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • COVID-19 / blood
  • COVID-19 Drug Treatment*
  • Female
  • Hematologic Neoplasms / blood
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Middle Aged
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • SARS-CoV-2*
  • Severity of Illness Index*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1